{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-086142","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.826852+00:00","generated_at":"2026-05-19T09:53:14.671607+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets","bullets":["Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.","Licensed anti-CCR8 (FG-3175) and anti-Gal-9 (FG-3165) intellectual property to HiFiBiO.","Eligible for mid single-digit to low double-digit share of HiFiBiO's sublicense revenues and low double-digit share of commercial royalties.","If HiFiBiO commercializes either asset, FibroGen receives single-digit royalties on worldwide net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-086142","json":"https://secwatch.observer/filing/0000950170-25-086142.json","markdown":"https://secwatch.observer/filing/0000950170-25-086142.md","text":"https://secwatch.observer/filing/0000950170-25-086142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/0000950170-25-086142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/fgen-20250612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T09:53:14.671607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}